The present invention provides methylenetetrahydrofolate reductase (MTHFR)
inhibitors for use in selective inhibition of cancer cell growth in a
mammal. These inhibitors can be a small molecule, an antisense
oligonucleotide, a ribozyme, a triple helix forming oligonucleotide, an
anti-MTHFR antibody or fragment thereof, an MTHFR mutant or a fragment of
MTHFR. The present invention further provides nucleic acids encoding an
inhibitor of MTHFR, and vectors comprising these nucleic acids. Also
encompassed by the present invention are methods of using the MTHFR
inhibitors for selective inhibition of cancer cell growth, and
pharmaceutical compositions comprising the MTHFR inhibitors.